What is HC Wainwright’s Estimate for SABS Q2 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – HC Wainwright issued their Q2 2025 earnings estimates for shares of SAB Biotherapeutics in a report released on Wednesday, May 14th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.58) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at ($0.33) EPS and FY2029 earnings at ($0.42) EPS.

Separately, Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of SAB Biotherapeutics in a research report on Thursday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and an average target price of $12.20.

SAB Biotherapeutics Stock Up 4.9%

Shares of SAB Biotherapeutics stock opened at $1.94 on Friday. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $5.01. The company has a market cap of $18.03 million, a P/E ratio of -0.52 and a beta of 0.47. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $1.51 and a 200 day moving average price of $2.52.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Friday, May 9th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.44. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Silver Oak Securities Incorporated bought a new stake in shares of SAB Biotherapeutics in the 1st quarter valued at approximately $30,000. Northern Trust Corp acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $43,000. Diadema Partners LP bought a new stake in SAB Biotherapeutics in the fourth quarter worth approximately $114,000. Geode Capital Management LLC increased its stake in shares of SAB Biotherapeutics by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after purchasing an additional 12,692 shares during the last quarter. Finally, HB Wealth Management LLC increased its position in SAB Biotherapeutics by 10.9% during the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after buying an additional 25,800 shares during the last quarter. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.